Global Biomarkers Market Forecast 2017-2027

LONDON, October 20, 2017 /PRNewswire/ --

Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases

The global biomarkers market is expected to grow at a CAGR of 9.1% in the first half of the forecast period. In 2016, the largest sector of the market was biomarker discovery, which encompasses revenues for instruments and reagents, as well as the other costs associated with in-house biomarker research and development. This sector accounted for 49.3% of the global biomarkers market.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 206-page report you will receive 66 tables and 59 figures- all unavailable elsewhere.

The 206-page report provides clear detailed insight into the global biomarkers market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope 

• Global Biomarkers Market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the global biomarkers market by Sector:
- Biomarker Services
- Biomarker Diagnostics
- Biomarker Discovery

• This report also breaks down the revenue forecast for the global biomarkers market by Discipline:
- Genomics
- Proteomics
- Bioinformatics
- Other

• This report also breaks down the revenue forecast for the global biomarkers market by Therapeutic Indication:
- Cancer
- Cardiovascular Diseases
- CNS,
- Autoimmune Diseases
- Other

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
- US
- EU5 (further segmented into France, Germany, the UK, Spain and Italy)
- Japan
- China
- India
- Russia
- Brazil
- RoW

• Our study gives qualitative analysis of the biomarkers market. It includes a SWOT and STEP Analysis.

• Our study discusses the selected leading companies that are the major players in the biomarkers industry. These companies are biomarker service providers, biomarker technology providers and biomarker diagnostic developers:
- Quintiles IMS Holdings Inc
- Laboratory Corporation of America Holdings
- Parexel
- Charles River Laboratories
- ICON plc
- WuXi PharmaTec
- Caprion Proteomics
- Proteome Sciences
- Pacific Biomarkers
- Oxford Gene Technology (OGT)
- Worldwide Clinical Trials (WWC)
- Agilent
- AB SCIEX
- QIAGEN
- Axela Inc
- Thermo Fisher Scientific
- Quest Diagnostics
- Myriad Genetics
- Genomic Health
- Critical Diagnostics
- Epigenomics
- MDxHealth (formerly OncoMethylome)

• Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs:
- Pfizer
- Novartis
- Roche Diagnostics
- Ventana Medical Systems
- Merck & Co.
- Sanofi
- GSK
- Abbott Laboratories
- AstraZeneca

Visiongain's study is intended for anyone requiring commercial analyses for the global biomarkers market. You find data, trends and predictions.

Buy our report today Global Biomarkers Market Forecast 2017-2027: Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases.

To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100

Or click on https://www.visiongain.com/Report/2029/Global-Biomarkers-Market-Forecast-2017-2027

List of Companies Mentioned in the Report 

454 Life Sciences (a subsidiary of Roche)

AB SCIEX

Abbott Laboratories

Abbott Molecular

Abcodia

ABT Molecular Imaging

ACS Biomarker

Advanced Cell Diagnostics (ACD)

Advion Bioanalytical Labs (part of Quintiles)

Affymetrix

Agendia

Agilent

Alacris Theranostics

Alere

Amarantus BioSciences

Amgen

Applied Biosystems (part of Life Technologies)

Aptiv Solutions

Arctic Partners

ARIAD Pharmaceuticals

Ariana Pharma

Arizona State University

Arrayit

ARUP Laboratories

AstraZeneca

Athena Diagnostics (a subsidiary of Quest Diagnostics)

Atherotech Diagnostics Lab

Aushon Biosystems

Axela Inc

Bayer

Belfer Institute for Applied Cancer Science [US]

Berkeley HeartLab (a subsidiary of Quest Diagnostics)

BG Medicine

BGI (formerly Beijing Genomics Institute)

Biofortis

Biosoft

BRAHMS (part of Thermo Fisher Scientific)

Brigham and Women's Hospital

Bristol-Myers Squibb

Cancer Research Technology

Caprion Proteomics

CBC (Comprehensive Biomarker Centre GmbH)

Celera (part of Quest Diagnostics)

Celgene

Cell Signaling Technology

Celldex Therapeutics

Cephalon (part of Teva)

Charles River Laboratories

Chronix Biomedical

Chugai Pharmaceutical

Ciphergen Biosystems

Clarient Diagnostic Services

Cleveland HeartLab

Clinigene International

Comprehensive Biomarker Center (formerly Febit)

Covance

Crelux

Critical Diagnostics

Critical Path Institute (C-Path) [US]

CTI Biotech

Daiichi Sankyo

Dako (now part of Agilent)

Dana-Farber Cancer Institute [US]

Danaher

DaVita Labs

DiaGenic

Durin Technologies

DxS (now part of QIAGEN)

EKO Diagnostic

Eli Lilly and Co.

Epic Sciences

Epigenomics

Epistem

EQT

Evotec

Exact Sciences

Exiqon

Exonhit

Ezose Sciences (part of Shionogi)

FEI Company

Foundation Medicine

Fujirebio Diagnostics

GE Healthcare

Genetic Technologies

Geneva Bioinformatics (GeneBio)

Genomic Health

GenWay Biotech

Great Point Partners

GSK

HD Biosciences

Health Diagnostic Laboratory

HealthLinx

Helicos BioSciences

Hewlett-Packard

HTG Molecular Diagnostics

ICON Plc

Illumina

ImmunId

Insight Genetics

Institute of Pathology Heidelberg (IPH)

Integrated Diagnostics

Ipsen

Ipsogen (a subsidiary of QIAGEN)

Isogen Life Science

Johnson & Johnson (J&J)

KU Leuven (University of Leuven)

LabCorp

Life Technologies

LightArray Biotech

M2Gen

Mayo Clinic [US]

Mayo Collaborative Services

MDxHealth

Medical Research Council [UK]

MediMedia Pharma Solutions

Memorial Sloan-Kettering Cancer Center [US]

Merck & Co.

Merck KGaA

Metabolon

Michael J Fox Foundation

Myriad Genetics

Myriad RBM (formerly Rules-Based Medicine, part of Myriad Genetics)

National Academy of Sciences (NAS) [US]

Nephromics

Novartis

Novartis Molecular Diagnostics (part of Novartis)

NovioGendix

Oncoimmune

Oncomedics

OpGen

OPKO Health

Orion Genomics

Oxford Cancer Biomarkers

Oxford Gene Technology

Pacific Biomarkers

Pacific Biosciences

Panomics (now part of Affymetrix)

Parexel

Patheon

Pathwork Diagnostics

Personal Genome Diagnostics

Pfizer

Pierre Fabre

PLUS Diagnostics

PMDA

Power3 Medical Products

PPD

Predictive Biosciences

Prometheus Laboratories

ProtagenAG 

Proteome Sciences

QIAGEN

QLIDA Diagnostics

Quanterix

Quanticel Pharmaceuticals

Quest Diagnostics

Quintiles

Quintiles IMS Holdings Inc

Randox Laboratories

Randox Laboratories

Roche

SABiosciences (now part of QIAGEN)

Sandor Proteomic

Sanger Institute

Sanofi

Santaris Pharma

Servier

Shionogi

Siemens

Siemens Healthcare

Singulex Inc

Sividion Diagnostics

SMA Foundation [US]

Stemina Biomarker Discovery

Sysmex

Technology Strategy Board (TSB) [UK]

Teva Pharmaceutical Industries

Thallion Pharmaceuticals

The Biomarkers Consortium

Thermo Fisher Sciences

Thermo Fisher Scientific

Transgene

Trans-Hit Biomarkers

Tufts Center for the Study of Drug Development

Ventana Medical Systems

Vertex Pharmaceuticals

WaferGen

Warnex

Worldwide Clinical Trials

WuXi AppTec

Wuxi Pharmatech

Xcovery

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain